Georgia CORE Research Network Sites Substantially Enroll in Abraxis (ABI-007)

8/02/2009

Community participation in the ABI-007 study currently accounts for 40 percent of the total enrollment. Northeast Georgia Cancer Care, LLC in Athens, GA recently enrolled an additional patient in the Abraxis Study: ABI-007, the neoadjuvant trial of Trastuzumab in combination with dose-dense ABI007 (Abraxane) followed by Vinorelbine. The study is open at the following Georgia CORE research network sites:

• Dekalb Medical/Georgia Cancer Specialists
• Emory/Winship Cancer Institute
• Georgia Cancer Center for Excellence/Grady Health System
• Northeast Georgia Cancer Care
• Piedmont Hospital/Peachtree Hematology Oncology Consultants.